Biotechnology

Bionomics

Bionomics released FY2025 Q1 earnings on November 14, 2024 (EST), with actual revenue of 0 and EPS of -0.0515

Bionomics receives FDA approval for Phase III clinical trial of BNC210 for PTSD

Bionomics to provide corporate update and discuss Phase 2 trial results of BNC210 in the treatment of post-traumatic stress disorder (PTSD) on July 31, 2024

Bionomics Limited develops new drugs for central nervous system diseases

Bionomics Launches Phase III Clinical Trial of BNC210, Results Expected in Q3 2025

Bionomics releases detailed data from the phase 2b ATTUNE trial of BNC210 for the treatment of post-traumatic stress disorder (PTSD)

Bionomics released FY2024 Q1 earnings on March 15, 2024 (EST), with actual EPS -0.6584 (forecast -0.594964)

PicoCELA

Santech

Highway

Trinity Biotech

Euda Health

Aimei Health Tech

Sable Offshore

Pomdoctor

Ascent Solar Tech

A SPAC III Acquisition

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap